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Background: We investigated the role of the HIPK2–p53 signaling pathway in tumorigenesis and resistance to the
drug Verbascoside (VB) in colorectal cancer (CRC), using in vivo and in vitro experiments.
Methods: Primary human CRC samples and normal intestinal tissues from patients were analyzed for HIPK2
expression by immunohistochemistry (IHC) and its expression was correlated against patients’ clinicopathological
characteristics. Human CRC HCT-116 cells were implanted in BALB/c nude mice; mice with xenografted tumors were
randomly administrated vehicle (control), 20, 40, or 80 mg/mL VB, or 1 mg/mL fluorouracil (5-FU). HIPK2, p53, Bax,
and Bcl-2 expression in these tumors were determined by IHC. In vitro effects of VB on CRC cell proliferation and
apoptosis were measured by CCK-8 assay and flow cytometry; HIPK2, p53, p-p53, Bax, and Bcl-2 were measured by
western blot.
Results: IHC analysis for 100 human CRC tumor samples and 20 normal intestinal tissues, showed HIPK2 expression
to inversely correlate with Dukes stage and depth of invasion in CRC (P < 0.05). In vivo, the inhibition rates of 20, 40,
and 80 mg/mL VB on CRC xenograft tumor weight were 42.79%, 53.90%, and 60.99%, respectively, and were
accompanied by increased expression of HIPK2, p53, and Bax, and decreased Bcl-2 expression in treated tumors.
In vitro, VB significantly inhibited proliferation of CRC cell lines HCT-116, HT-29, LoVo, and SW620, in a time- and
dose-dependent manner. The apoptosis rates of 25, 50, and 100 μM VB on HCT-116 cells were 10.83 ± 1.28, 11.25 ±
1.54, and 20.19 ± 2.87%, and on HT-29 cells were 18.92 ± 6.12, 21.57 ± 4.05, and 25.14 ± 6.73%, respectively. In summary,
VB treatment significantly enhanced the protein expression of pro-apoptotic HIPK2, p53, p-p53, Bax, and decreased
anti-apoptotic Bcl-2 expression in CRC cells.
Conclusions: HIPK2 protein modulates the phosphorylation status of p53, and levels of Bax and Bcl-2 in CRC. We also
found that VB effectively activated the HIPK2–p53 signaling pathway, resulting in increased CRC cell apoptosis.
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Colorectal cancer (CRC) is one of the most common
malignancies in the world. With economic development
and lifestyle changes, the incidence of CRC has been
increasing yearly, with a significant rising rate. According
to Global Cancer Statistics 2011, the incidence of CRC
ranked third among male cancer patients and second
among female cancer patients. In 2011, people who died
from CRC accounted for 8% of all cancer deaths. It is the* Correspondence: lzwf@hotmail.com
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unless otherwise stated.fourth most common cause of cancer death [1]. In China,
the rate of CRC incidence is increasing faster nationally
than all other cancers. In the Shanghai area, CRC went
from the fourth most common cancer in 1980s to the
third most common in the 1990s [2] and by 2009 had
become the second most common cancer in Shanghai [3].
Various factors contribute to CRC development, in-
cluding intestinal mucosa losing normal growth control
at the genetic level, leading to cell hyperproliferation.
Most recent investigations of CRC tumorigenesis have
therefore focused on functional abnormalities of relevant
genes and their products.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a member of the serine/threonineproteinkinase family, lo-
cated inside the cell nucleus. It is a transcription mediator
that interacts with homobox plastein. Reportedly, HIPK2
is associated with late embryogenesis, and neural, retinal,
and muscle tissue development, and also participates
in various aspects of tumorigenesis, including oncogene
expression [4], apoptosis [5], angiogenesis [6], and multi-
drug resistance [7-9].
HIPK2 is a key regulator of numerous transcription
factors, including p53, in DNA damage signaling path-
ways. HIPK2 co-localizes with p53in nucleosomes and
phosphorylates Ser46 of p53. Using a microarray assay,
Puca et al. found that HIPK2 knockdown in colon cancer
cells led to the loss of target gene activation of wild-type
p53 [10]. They also identified misfolding of p53 protein,
and impaired p53–DNA binding and transcription of
target genes. HIPK2 stimulates p300 and lys382-p53
for co-recruitment onto apoptosis promoters. By balan-
cing p53 acetylation and deacetylation, HIPK2 regulates
p53 apoptosis-promoting transcription activity [11].
McDonough et al. found HIPK2interacts with DAXX, a
p53-binding protein, to inhibit binding with downstream
effect or proteins, thus activating Ser46 phosphorylation
and promoting p53 apoptotic signaling [12].
Verbascoside (VB), an active constituent of a Chinese
traditional medical plant genus, Cistanche, has been
shown to have anti-cancer activity in treating CRC,
stomach [13], breast [14,15], prostate [16], melanoma
[17], glioma [18], and other cancers. Cistanche, as a
common clinical treatment for CRC, inhibits post-operative
tumor recurrence, tumor invasion and metastasis, although
the underlining mechanisms are not yet well understood.
In this study, we analyzed HIPK2 expression in primary
tumor specimens of human CRC, with particular regard
to post-operative cancer recurrence, metastasis, and ma-
lignancy grades. We used a xenograft CRC mouse model
to test the in vivo anti-tumor effect of VB and measured
protein levels of HIPK2 and p53, and apoptosis-related
gene products Bax and Bcl-2. We also show that VB
inhibits cell proliferation and promotes apoptosis in CRC
by stimulating the HIPK2–p53 signaling pathway.
Methods
Cell culture
Human CRC cell lines HCT-116, LoVo, HT-29, and
SW62were purchased from the Chinese Academy of
Science. HCT-116 and LoVo were cultured in RPMI-1640
medium with 10% fetal bovine serum (FBS), HT-29 and
SW620 were cultured in McCoy’s 5A medium with 10%
FBS. All cells were cultured with 100 μg/mL streptomycin
(Invitrogen, Carlsbad, CA, USA) at 37°C in a 5% CO2
humidified incubator (Thermo Fisher Scientific Inc.,
Waltham, MA, USA).Human tissue samples
Human CRC tumor and normal tissue samples were
collected from the General Surgery Department of our
hospital from January 2011 to February 2012. All the
experiments and animal care were approved by Shanghai
Medical Experimental Animal Care Commission and in
accordance with the Provision and General Recommenda-
tion of Chinese Experimental Animals Administration
Legislation. The tissues were immediately frozen in liquid
nitrogen and later preserved at −80°C for long-term stor-
age. The use of all human tissue samples was approved by
the Institutional Review Board of the Shuguang Hospital
affiliated to Shanghai University of Traditional Chinese
Medicine. We obtained consent from every patient, for
the use of all human tissues used in this study.
Animals
BALB/c nude male mice, aged 4–6 weeks and weighing
18–20 g, were purchased from Sino-British SIPPR/BK
lab Animal Co., Ltd (Shanghai, China, license No. SCXK
2008–0016). All animal protocols were approved by the
Institutional Animal Use and Care Committee of Shanghai
University of Traditional Chinese Medicine. Breeding
conditions of the SPF Animal Laboratory were: free ac-
cess to food and water, ventilation, humidity at 50–65%,
temperature at 22–24°C, 12 h of light/dark. The animal
laboratory abided by related regulations of the Animal
Ethics Committee.
Immunohistochemical staining
The human CRC tumor and normal tissue samples were
paraffin embedded and serially sectioned. Tissue sections
were processed by de-paraffining, rehydrating through
an alcohol gradient, peroxidase clearing, antigen re-
trieval and blocking, antibody binding, DAB staining,
washing with distilled water, hematoxylin staining, nia-
cin alcohol differentiation, dilute ammonia bluing,
incremental graded alcohol dehydration, xylene and
conventional resin mounting. The primary antibody
was rabbit-anti-human HIPK2 monoclonal antibody
diluted by 1:50 (Abcam, Cambridge, MA, USA). The
secondary biotin-labeled antibody was used at 1:200.
For color development, streptavidin was labeled with
horseradish peroxidase at 1:200. Under 400 × magnifi-
cation, five random fields were selected. Staining was
assessed as: non-staining: 0 point; light brown: 1 point;
brownish yellow: 2 points; and dark brown: 3points.
Percentages of positive-stained cells were rated as:
positive cells ≤5%: 0 point; 6–25%: 1 point; 26–50%:2
points; and ≥75%: 3 points. Points for staining and per-
centage were multiplied for a 10-point scale: 0 point:
negative (−), 1–3 points: weakly positive (+); 4–6
points: positive (++); and 7–9 points: strongly positive
(+++).
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Human CRC HCT-116, LoVo, HT-29, and SW620 cells
in logarithmic growth phases were plated at 5 × 103
cells/well in 96-well plates; the next day, culture media
was replaced with 200 μL culture medium containing
VB (purity >98%, purchased from Chendu Herb purify
Biotechnology Co., Ltd, Chendu, China, serial number:
20100123), with concentrations of 12.5, 25, 50, 100, 150,
or 200 μM. For each concentration, 12 ventral orifices
were set. After 24 h, 48 h, and 72 h, 20 μL of CCK-8
reagent (Dojindo Molecular Technologies, Inc., Tokyo,
Japan) was added into each well. Four hours later, the
light absorption value of each well at 490 nm was mea-
sured in a microplate reader (Bio-Rad Laboratories,
Philadelphia, PA, USA). The inhibition rate of VB on the
growth of CRC cells was calculated as the following
equation: GIR = [1− (ODN −OD0)/(ODC −OD0) ] × 100%;
where OD0 was the absorbance value of the blank group,
ODC the control group, and ODN groups with different
doses of VB. The IC50 of VB was calculated using three in-
dependent experiments.
Apoptosis measured by flow cytometry
Rapid growing HCT-116 and HT-29 cells were treated
with VBat different concentrations (25, 50, or 100 μM)
for 48 h. Cells were then stained with 2 μL Annexin-V
and 2 μL PI in 50 μL of apoptosis reaction solution at
4°C for 30 min. FACScan flow cytometry was used to
detect apoptotic cells. Cell debris in different quadrants
was calculated statistically. Cells in the upper rightFigure 1 Representative HIPK2 IHC staining in normal and colorectal
(−and +, Figure 1A), high HIPK2 protein expression in normal tissue (++ an
tissue (−and +, Figure 1C) and high expression incolorectal tumor tissue (+quadrant represented early apoptosis; cells in the lower
right quadrant represented late apoptosis.
In vivo xenografic CRC model
HCT-116 cells (2 × 106/mouse) were injected subcutane-
ously into the right axilla of nude mice. Ten to 14 days
later, when tumors formed, the nude mice with good
growth state and unbroken tumors were used as tumor
supply mice, and were then sacrificed. Tumors were
dissected out under aseptic conditions, with necrotic
and fibrous tissues removed. Fresh parts on the edge of
tumors were cut into 1-mm3tumor blocks, which were
implanted under the axillar skin of the right front legs
of nude mice. With this method, three generations of
mice were produced. The third-generation mice with
unbroken transplanted tumor and sound growth state
were sacrificed, and using the above-described method,
the tumors were re-implanted and when they reached
a size of 50–100 mm3, the tumor-bearing mice were
randomly divided into five groups (six mice for each
group): the control group (isometric normal saline),
the low-, medium-, and high-dose VB groups (20, 40,
and 80 mg/kg/day, respectively) and the fluorouracil
(5-FU) group (1 mg/kg/day). VBand 5-FU were admin-
istered by tail vein injection. At days 1, 4, 7, 10, and 14,
the long diameter (a) and the short diameter (b) of
each tumor was measured, and tumor volume was cal-
culated as [(a × b2)/2]. After 14 days of treatment, mice
were sacrificed and their tumors were dissected and
connective tissues were removed. The tumors weretumor tissue. Low HIPK2 protein expression in the normal tissue
d +++, Figure 1B). Low HIPK2 protein expression in colorectal tumor
+ and +++, Figure 1D). Magnification × 200.
Table 1 Differential expression of HIPK2 in cancerous and
normal colorectal tissues
Group N
Expression of HIPK2 (%)
P
Low High
Normal colorectal tissues 20 40% 60%
0.003
Colorectal cancer tissues 100 74% 26%
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rates [(1− average tumor volume of the experimental
group/average tumor volume of the control group) ×
100%]; and the tumor weight inhibition rates [(l − average
tumor weight of the experimental group/average tumor
weight of the control group) × 100%].
Protein extraction and western blot
Western blot analyses were conducted as previously















Well differentiated 12 7
Moderately differentiated 67 33
Poorly differentiated 5 1
Depth of invasion
Not invading serosa 42 28
In serosa 25 6
Outside serosa 33 15
Duke stage
Stages A and B 72 35
Stages C and D 28 14
Lymph node status
Metastasis 65 32
No metastasis 35 17
TNM stage
Stages I and II 57 31
Stages III and IV 43 18by VB (25, 50, and 100 μM) for 48 h, before being lysed
and total protein was extracted. Protein samples were
separated with 10%SDS-PAGE gel, transferred to a
PVDF membrane with a Trans-Blot (Bio-Rad). The
membrane was probed with primary antibodies (1: 1000
of anti-HIPK2, 1: 1000 of anti-P53, 1: 1000 of anti- p-p53,
1:1000 of anti-Bax, 1: 1000 of anti-Bcl-2, or 1: 4000 of
anti-β-actin; Cell Signaling Technology, Danvers, MA,
USA). The signal intensities of protein abundance were
quantitatively analyzed by Image J.
Statistical analysis
Software SPSS18.0 was used for statistical data analysis.
The data was expressed with x ± s. If data met the homo-
geneity of variance of Gaussian distribution, we used one-
way analysis of variance for statistical inference; otherwise,
we used non-parametric tests. The test criterion α = 0.05,
P < 0.05 was considered statistically significant.and HIPK2 expression in human CRC
fferent HIPK2 expression levels
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Table 3 Effect of Verbascoside on expression levels of
apoptosis-related proteins in CRC xenograft tumors
Groups n
Relative protein expression level
HIPK2 P53 Bax Bcl-2
Control 6 3.23 ± 0.61 11.70 ± 2.08 9.82 ± 0.55 17.43 ± 1.50
20 mg/kg VB 6 4.83 ± 0.62 14.59 ± 0.90 14.41 ± 0.38 14.08 ± 1.04
40 mg/kg VB 6 8.46 ± 0.99 17.60 ± 1.40 15.84 ± 0.54 11.93 ± 0.93
80 mg/kg VB 6 11.90 ± 1.21 23.10 ± 2.10 26.28 ± 0.55 7.48 ± 0.86
1 mg/kg 5-FU 6 13.50 ± 0.94 22.44 ± 2.05 26.34 ± 2.33 5.46 ± 0.67
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HIPK2 protein levels and CRC clinicopathologic features
are inversely associated
In 100 cases of human CRC cancer samples, 74 expressed
low levels of HIPK2 protein (−and +, Figure 1A) and
26showed high expression (++ and +++, Figure 1B). In 20
cases of normal colorectal cancer tissues, eight had low
HIPK2 protein expression (−and +, Figure 1C) and 12had
high expression (++ and +++, Figure 1D). Expression of
HIPK2 was significantly higher in normal tissues than in
CRC tissues (Table 1). We further found that HIPK2 pro-
tein expression in human CRC significantly correlated
with the degree of differentiation (Table 2). However, the
HIPK2 expression levels were not significantly associated
with sex, age, maximum tumor diameter, Dukes staging,
degree of cancer infiltration, or number of metastasized
lymph nodes.Figure 2 Verbascoside (VB) inhibited in vivo growth of CRC tumor in
in nude mice treated with different doses of VB and 5-FU at 1, 4, 7, 9, 12, a
treatment groups (B). Xenograft tumor volumes of mice treated with indicated
137.7 ± 37.5 mm3, 128.1 ± 40.2 mm3, and87.9 ± 62.0 mm3(C), and xenogra
respectively: 0.423 ± 0.150 g, 0.242 ± 0.135 g, 0.195 ± 0.057 g, 0.165 ± 0.065Pro-apoptotic effects of VB in CRC xenograft tumors
To investigate the tumor inhibitory activity of VB for
CRC, we first established a human CRC xenograft mode
in mice, which were then treated with different doses of
VB. In vivo data showed that VB remarkably inhibited
growth of the xenografted tumors (Figure 2A and B).a dose- and time-dependent manner. Growth of xenograft tumors
nd 15 days (A). Dissected tumor samples from nude mice in different
doses of VB and 5-FU, respectively: 353.4 ± 124.8 mm3, 182.4 ± 54.5 mm3,
ft tumor weights of mice treated with indicated doses of VB and 5-FU,
g, and 0.143 ± 0.067 g (D). P < 0.05.
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high-VB dose groups were 48.41%, 61.04%, and 63.75%,
respectively; and tumor weight inhibition rates were
42.79%, 53.90%, and 60.99%, respectively (Figure 2C, D).
Notably, at higher doses, the anti-tumor effect of VB was
similar to that of 5-FU (Figure 2). The VB-treated tumor
samples were then analyzed by IHC for levels of
apoptosis-related proteins such as HIPK2, p53, Bax, and
Bcl-2. The results indicated that VB significantly enhanced
expression of pro-apoptotic HIPK2, p53, and Bax proteins
in tumors, but decreased expression of anti-apoptotic pro-
tein Bcl-2, in a dose-dependent manner (Table 3, Figure 3).
In vitro inhibitory effect of VBon CRC cells
We next tested whether VB affected in vitro growth of
CRC cell lines. After 24, 48, and 72 h of VB treatment,
the growth of CRC cells HCT-116, LoVo, HT-29, and
SW620 was dramatically inhibited, in a time- and dose-
dependent manner, with an IC50of 29–67 μM after 72 h
(Figure 4).Figure 3 Expression of apoptosis-related proteins is affected by Verb
Bax, and Bcl-2 proteins in tumors treated with VB (A). Relative protein expr
(B). Magnification × 200.VB promoted apoptosis via p53 in human CRC cells
Based on the cell proliferation inhibition data, we se-
lected 48-htreatment of CRC HCT-116 and HT-29 as
the optimal time frame for apoptosis experiments. We
used drug doses of 25, 50, and 100 μM of VB to treat
cells for 48 h (Figure 5A, B), and used FITC Annexin-V/PI
method to measure apoptosis induced by VB. Our data
showed the apoptosis rate to be significantly increased by
VB in a dose-dependent manner (Figure 5C). Interestingly,
this pro-apoptotic effect by VB was countered by a p53-
specific inhibitor, FPT-a (Figure 5D). This suggests that VB
promotes apoptosis in CRC cells through ap53-dependent
mechanism.
VB promotes apoptosis in human CRCviaHIPK2–p53signaling
pathway
We next determined if expression levels of apoptosis-
related proteins changed in VB-treated human CRC cells
HCT-116 and HT-29. We found, after 48 h of treatment,
VB increased protein expression of HIPK2, p53, p-p53,ascoside (VB) in CRC xenograft tumors. IHC staining of HIPK2, p53,
ession levels in (A) were quantified by image analysis software
Figure 4 Inhibitory effect of Verbascoside (VB) on different human CRC cell lines, at indicated doses and durations. The IC50 doses of VB on
human CRC cells at 24, 48, and 72-h culture, respectively, were 208.89 μmol/L, 97.86 μmol/L and 63.51 μmol/L in HCT-116 cells (A); 83.83 μmol/L,
59.62 μmol/L, and 43.96 μmol/L in LoVo cells (B); 144.5 μmol/L, 108.82 μmol/L, and 66.68 μmol/L in HT-29 cells (C); and 52.73 μmol/L, 42.42 μmol/L,
and 29.05 μmol/L in SW620 cells (D).
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manner in the CRC cell lines (Figure 6A). These data both
recapitulated the results we saw in the VB-treated CRC tu-
mors in vivo, and further indicated that VB promotes
apoptosis in CRC, probably through HIPK2–p53signaling
axis. To verify this point, we added the p53-specific inhibi-
tor PFT-a to the treated cells along with VB. The results
showed that PFT-a rescued the cells from VB-induced
apoptosis, by reducing VB-enhanced protein levels of
p-p53 on Ser46, Bax, and restoring Bcl-2 protein expres-
sion, but did not affect HIPK2 protein levels (Figure 6B).
These findings strongly suggest that VB-induced apoptosis
is mediated by the HIPK2–p53signaling pathway.
Discussion
Apoptosis is a response of cells to internal and external
signals under certain physiological and pathological
circumstances, to maintain homeostasis [21]. Many anti-
cancer drugs attack tumors by triggering apoptosis [22].
Mechanisms of drug-induced tumor apoptosis includealtering cell signaling pathways, expression levels of
tumor-suppressor oncogene products, and influencing
other apoptosis-promoting and -inhibiting proteins.
Anti-cancer drugs can also block the cell cycle and inhibit
cell growth, while activating caspase cascades and modu-
lating telomerase expression and activity [23-25].
As a newly found auxiliary transcription inhibition fac-
tor, HIPK2 has been suggested to affect many aspects of
cancer. Studies showed that HIPK2 participates in a var-
iety of signal transduction pathways, including p53 [26],
Wnt/β-catenin [27], JNK [28], and hypoxiainducible factor
[11,29,30]. Recent studies suggest that HIPK2 influences
apoptosis through a variety of mechanisms, especially the
p53-mediated apoptosis signaling cascade [19,20]. p53 is
the most important tumor-suppressor gene, and is impli-
cated in regulation of apoptosis; its protein is activation is
controlled by post-translational modifications, such as
phosphorylation, acetylation, and interactions with other
proteins. p53 phosphorylation not only stabilizes and en-
hances the transcription activity of p53, but also regulates
Figure 5 (See legend on next page.)
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Figure 5 Verbascoside (VB) promoted apoptosis via p53 in human CRC cells. CRC HCT-116 and HT-29 cells were treated by VB at indicated
doses and duration, and then analyzed for apoptosis by flow cytometry. Inhibition at 25, 50, and 100 μM of VB to HCT-116 cells was 20.20 ± 4.08%,
43.28 ± 9.80%, and 56.79 ± 9.11% (A), and HT-29 cells, 4.36 ± 3.39%, 18.22 ± 3.94%, and 37.01 ± 6.98%, respectively (B). HCT-116 apoptosis rate
after being treated with 25, 50, and 100 μM of VB was 10.83 ± 1.28%, 11.25 ± 1.54%, and 20.19 ± 2.8%, and the HT-29 apoptosis rate, 18.92 ± 6.12%,
21.57 ± 4.05%, and 25.14 ± 6.73%, respectively (C). HCT-116 and HT-29 apoptosis rate was 11.25 ± 1.54% and 21.57 ± 4.05% after being treated with
50 μM Verbascoside; and 5.03 ± 2.77% and 3.11 ± 1.16% after being treated with FPT-a (p53-specific inhibitor); and 5.02 ± 0.73% and 3.18 ± 1.82% after
being treated with FPT-a and 50 μM VB respectively (D).
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ation is critical to transcription of apoptosis-related genes.
HIPK2 overexpression stabilizes and activatesp53 and
promotes its binding to form the HIPK2–p53 complex,
leading to Ser46 phosphorylation and increased apop-
tosis [31].
We conducted a retrospective analysis on 100 primary
CRC tumor samples, and found that the average age of
CRC diagnosis was 67.25 ± 11.91 years, which did not
significantly vary by sex. Common symptoms of CRC
include changes in bowel habits, hemafecia/melena, and
abdominal pain or discomfort. Among them, hemafecia
is the most common symptom, seen in 93.75% of pa-
tients with CRC. As for the clinicopathological fea-
tures, the average tumor diameter was 5.31 ± 2.21 cm,Figure 6 Verbascoside (VB) alters levels of HIPK2–p53apoptosis signa
extracts were probed for HIPK2, p53, p-p53, Bax, and Bcl-2 protein (A), andwith glandular cancer as the most common histology
(91%), and ulcerative type as the major morphological
type (37%). IHC analyses showed HIPK2 expression in
normal colorectal mucosal tissues to be higher than in
CRC samples. These data are consistent with previous
reports showing a similar pattern for HIPK2 expressions
in breast cancer and thyroid cancer [32-34]. Correlation
analysis showed that HIPK2 expression was closely as-
sociated with Dukes staging and infiltration degrees,
but not to sex, age, degree of differentiation, or lymph
node metastasis.
We next tested VB’s anti-tumor activity in an in vivo
mouse model of human CRC, and found VB to significantly
inhibit xenograft tumor growth. IHC analyses showed
heightened levels of pro-apoptotic proteins HIPK2, p53,ling molecules in CRC cells. HCT-116 and HT-29 cells treated with VB
were compared with cells treated with both VB extracts and PFT-a (B).
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results imply that VB promotes cancer cellapoptosis
throughHIPK-2- and p53-related signaling. To study the
mechanisms of this anti-cancer effect, we used VB to
treat human CRC cell lines. As with the in vivo studies,
VB had a remarkable anti-proliferative and apoptosis-
promoting effect in HCT-116, HT-29, LoVo, and
SW620 cells, in a time- and dose-dependent manner. In
addition, this nicely correlates with the previous finding
that VB induces genotoxic stress [35].
Reportedly, theHIPK2–p53 apoptotic pathway is down-
regulated in different human cancer cells [36-42]. In inves-
tigating the mechanisms that underpin VB-promoted
apoptosis, we first learned that both in CRC tumors and
cells, VB elevated HIPK2 protein levels. Additionally,
levels of p53, p-p53 at Ser46, and downstream pro-
apoptosis Bax protein were greatly boosted, whereas
anti-apoptosis Bcl-2 protein expression was reduced, by
VB treatment. Furthermore, the pro-apoptotic action of
VB was obscured by a p53-specific inhibitor, which restored
protein levels of p-p53 (Ser46), p53, Bax, and Bcl-2 to the
untreated status. Interestingly, HIPK2 protein expression
was not influenced. To summarize, our data suggest that
VB promotes p53 phosphorylation and Bax expression and
inhibits Bcl-2 expression by increasing HIPK2 levels in
CRC, which leads to activation of theHIPK2–p53 signaling
pathway and increased apoptosis.Conclusions
In summary, we found that HIPK2 expression inversely
correlates with primary CRC, Dukes staging, and infiltra-
tion degrees. We also found that VB significantly inhibits
CRC growth in vivo, and represses CRC cell proliferation,
and promotes apoptosis, by modulating the HIPK2–p53
signaling pathway.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
QL and LZ designed the overall program. LZ designed the in vivo
experiments. XC performed most of the in vitro experiments with help from
YF, YJ, XL, FH, and QJ. HS, YW, and NL performed the in vivo experiments.
HS, LZ, and QL wrote the manuscript, which was then reviewed and
approved by all other authors.
Acknowledgments
This study is supported by the National Natural Science Foundation of China
(No.81303106), the Science Foundation for Shanghai Committee of Science
Project (Nos.13140902500, 13ZR1462200), the Shanghai Health Bureau
Science Foundation (No.20124048), and the Shanghai Municipal Education
Commission (Nos. 12YZ058, 12ZZ118).
Author details
1Department of Medical Oncology, Shuguang Hospital, Shanghai University
of Traditional Chinese Medicine, Shanghai 201203, China. 2Cancer Institute
and Longhua Hospital, Shanghai University of Traditional Chinese Medicine,
Shanghai 200032, China.Received: 6 January 2014 Accepted: 26 September 2014
Published: 5 October 2014References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Liu EJ, Xiang YB, Jin F, Zhou SZ, Sun L, Fang RR, Yuan ZX, Gao LF, Gao YT:
Cancer incidence trends in urban Shanghai, 1972–1999. Tumor 2004,
24:11–15.
3. Shanghai Municipal Center for Disease Control & Prevention: Cancer
incidence of Shanghai, 2009. Shanghai J Prev Med 2013, 25:54–55.
4. Wang Y, Debatin KM, Hug H: HIPK2 overexpression leads to stabilization
of p53 protein and increased p53 transcriptional activity by decreasing
Mdm2 protein levels. BMC Mol Biol 2001, 2:8.
5. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D’Orazi G: Homeodomain-
interacting protein kinase-2 activity and p53 phosphorylation are critical
events for cisplatin- mediated apoptosis. Exp Cell Res 2004, 293:311–320.
6. Nardinocchi L, Puca R, Givol D, D’Orazi G: HIPK2-a therapeutical target to
be (re) activated for tumor suppression: role in p53 activation and
HIF-1α Inhibition. Cell Cycle 2010, 9:1270–1275.
7. Puca R, Nardinocchi L, D’Orazi G: Regulation of vascular endothelial
growth factor expression by homeodomain-interacting protein kinase-2.
J Exp Clin Cancer Res 2008, 27:1–7.
8. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z: MiR-27a modulates
MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian
cancer cells. Gynecol Oncol 2010, 119:125–130.
9. Kim EJ, Park JS, Um SJ: Identification and characterization of HIPK2
interacting with p73 and modulating functions of the p53 family in vivo.
J Biol Chem 2002, 277:32020–32028.
10. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman
DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D, D’Orazi G: Reversible
dysfunction of wild-type p53 following homeodomain-interacting protein
kinase-2 knockdown. Cancer Res 2008, 68:3707–3714.
11. Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D, D’Orazi G: HIPK2
modulates p53 activity towards pro-apoptotic transcription. Mol Cancer
2009, 8:85.
12. McDonough H, Charles PC, Hilliard EG, Qian SB, Min JN, Portbury A, Cyr DM,
Patterson C: Stress-dependent Daxx-CHIP interaction suppresses the p53
apoptotic program. J Biol Chem 2009, 284:20649–20659.
13. Obied HK, Prenzler PD, Konczak I, Rehman AU, Robards K: Chemistry and
bioactivity of olive biophenols in some antioxidant and antiproliferative
in vitro bioassays. Chem Res Toxicol 2009, 22:227–234.
14. Quirantes-Piné R, Zurek G, Barrajón-Catalán E, Bäßmann C, Micol V,
Segura-Carretero A, Fernández-Gutiérrez A: A metabolite-profiling
approach to assess the uptake and metabolism of phenolic compounds
from olive leaves in SKBR3 cells by HPLC-ESI-QTOF-MS. J Pharm Biomed
Anal 2013, 72:121–126.
15. Harput US, Genc Y, Saracoglu I: Cytotoxic and antioxidative activities of
Plantago lagopus L. and characterization of its bioactive compounds.
Food Chem Toxicol 2012, 50:1554–1559.
16. Kirmizibekmez H, Ariburnu E, Masullo M, Festa M, Capasso A, Yesilada E,
Piacente S: Iridoid, phenylethanoid and flavonoid glycosides from
Sideritis trojana. Fitoterapia 2012, 83:130–136.
17. Funari CS, Passalacqua TG, Rinaldo D, Napolitano A, Festa M, Capasso A,
Piacente S, Pizza C, Young MC, Durigan G, Silva DH: Interconverting
flavanone glucosides and other phenolic compounds in Lippia
salviaefolia Cham. ethanol extracts. Phytochemistry 2011,
72:2052–2061.
18. Esposito E, Dal Toso R, Pressi G, Bramanti P, Meli R, Cuzzocrea S: Protective
effect of verbascoside in activated C6 glioma cells: possible molecular
mechanisms. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:93–105.
19. Dauth I, Krüger J, Hofmann TG: Homeodomain-interacting protein kinase 2 is
the ionizing radiation-activated p53 serine 46 kinase and is regulated by
ATM. Cancer Res 2007, 67:2274–2279.
20. Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, Crone J,
Hofmann TG: Control of HIPK2 stability by ubiquitin ligase Siah-1 and
checkpoint kinases ATM and ATR. Nat Cell Biol 2008, 10:812–824.
21. Yao J, Qian CJ, Ye B, Zhang X, Liang Y: ERK inhibition enhances TSA-induced
gastric cancer apoptosis via NF-κB-dependent and Notch-independent
mechanism. Life Sci 2012, 91:186–193.
Zhou et al. BMC Cancer 2014, 14:747 Page 11 of 11
http://www.biomedcentral.com/1471-2407/14/74722. Gangemi G, Gazzerro P, Fiore D, Proto MC, Butini S, Gemma S, Casagni A,
Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Clive
Williams D, Campiani G, Bifulco M: PBOX-15 induces apoptosis and
improves the efficacy of oxaliplatin in human colorectal cancer cell lines.
Eur J Pharmacol 2013, 714:379–387.
23. Cheng TC, Lu JF, Wang JS, Lin LJ, Kuo HI, Chen BH: Antiproliferation effect
and apoptosis mechanism of prostate cancer cell PC-3 by flavonoids
and saponins prepared from Gynostemma pentaphyllum. J Agric Food
Chem 2011, 59:11319–11329.
24. Pongjit K, Chanvorachote P: Caveolin-1 sensitizes cisplatin-induced lung
cancer apoptosis via superoxide anion-dependent mechanism. Mol Cell
Biochem 2011, 358:365–373.
25. Du WW, Yang BB, Yang BL, Deng Z, Fang L, Shan SW, Jeyapalan Z, Zhang Y,
Seth A, Yee AJ: Versican G3 domain modulates breast cancer apoptosis: a
mechanism for breast cancer cell response to chemotherapy and EGFR
therapy. PLoS One 2011, 6:e26396.
26. Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol D, D’Orazi G:
Nox1 is involved in p53 deacetylation and suppression of its
transcriptional activity and apoptosis. Free Radic Biol Med 2010,
48:1338–1346.
27. Kim EA, Kim JE, Sung KS, Choi DW, Lee BJ, Choi CY: Homeodomain-
interacting protein kinase 2 (HIPK2) targets beta-catenin for
phosphorylation and proteasomal degradation. Biochem Biophys Res
Commun 2010, 394:966–971.
28. Hofmann TG, Stollberg N, Schmitz ML, Will H: HIPK2 regulates
transforming growth factor-beta-induced c-Jun NH (2)-terminal kinase
activation and apoptosis in human hepatoma cells. Cancer Res 2003,
63:8271–8277.
29. Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, Michiels C, Sacchi A,
Onisto M, D’Orazi G: Transcriptional regulation of hypoxia-inducible factor
1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth.
Biochim Biophys Acta 2009, 1793:368–377.
30. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D’Orazi G: Targeting hypoxia
in cancer cells by restoring homeodomain interacting protein-kinase 2 and
p53 activity and suppressing HIF-1alpha. PLoS One 2009, 4:e6819.
31. D’Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa
M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S:
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser
46 and mediates apoptosis. Nat Cell Biol 2002, 4:11–19.
32. Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, Garufi A,
Rechavi G, Givol D, D’Orazi G: HIPK2 downregulates vimentin and inhibits
breast cancer cell invasion. Cancer Biol Ther 2012, 13:198–205.
33. Wesierska-Gadek J, Schmitz ML, Ranftler C: Roscovitine-activated HIP2
kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7
breast cancer cells. J Cell Biochem 2007, 100:865–874.
34. Lavra L, Rinaldo C, Ulivieri A, Luciani E, Fidanza P, Giacomelli L, Bellotti C,
Ricci A, Trovato M, Soddu S, Bartolazzi A, Sciacchitano S: The loss of the
p53 activator HIPK2 is responsible for galectin-3 overexpression in well
differentiated thyroid carcinomas. PLoS One 2011, 6:e20665.
35. Santoro A, Bianco G, Picerno P, Aquino RP, Autore G, Marzocco S, Gazzerro P,
Lioi MB, Bifulco M: Verminoside- and verbascoside-induced genotoxicity on
human lymphocytes: involvement of PARP-1 and p53 proteins. Toxicol Lett
2008, 178:71–76.
36. Hofmann TG, Möller A, Sirma H, Zentgraf H, Taya Y, Dröge W, Will H,
Schmitz ML: Regulation of p53 activity by its interaction with
homeodomain-interacting protein kinase-2. Nat Cell Biol 2002, 4:1–10.
37. Li Q, Lin S, Wang X, Lian G, Lu Z, Guo H, Ruan K, Wang Y, Ye Z, Han J, Lin
SC: Axin determines cell fate by controlling the p53 activation threshold
after DNA damage. Nat Cell Biol 2009, 11:1128–1134.
38. Crone J, Glas C, Schultheiss K, Moehlenbrink J, Krieghoff-Henning E, Hofmann
TG: Zyxin is a critical regulator of the apoptotic HIPK2–p53 signaling axis.
Cancer Res 2011, 71:2350–2359.
39. Gresko E, Roscic A, Ritterhoff S, Vichalkovski A, del Sal G, Schmitz ML:
Autoregulatory control of the p53 response by caspase-mediated
processing of HIPK2. EMBO J 2006, 25:1883–1894.
40. Bitomsky N, Conrad E, Moritz C, Polonio-Vallon T, Sombroek D,
Schultheiss K, Glas C, Greiner V, Herbel C, Mantovani F, del Sal G, Peri F,
Hofmann TG: Autophosphorylation and Pin1 binding coordinate DNA
damage-induced HIPK2 activation and cell death. Proc Natl Acad Sci
U S A 2013, 110:E4203–E4212.41. Kumar N, Wethkamp N, Waters LC, Carr MD, Klempnauer KH: Tumor
suppressor protein Pdcd4 interacts with Daxx and modulates the
stability of Daxx and the Hipk2-dependent phosphorylation of p53 at
serine 46. Oncogene 2013, 2:e37.
42. Mao JH, Wu D, Kim IJ, Kang HC, Wei G, Climent J, Kumar A, Pelorosso FG,
Del Rosario R, Huang EJ, Balmain A: HIPK2 cooperates with p53 to
suppress γ-ray radiation-induced mouse thymic lymphoma. Oncogene
2012, 31:1176–1180.
doi:10.1186/1471-2407-14-747
Cite this article as: Zhou et al.: Verbascoside promotes apoptosis by
regulating HIPK2–p53 signaling in human colorectal cancer. BMC Cancer
2014 14:747.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
